Overview
Densitas Inc. is a Halifax, Nova Scotia-based company specializing in the development of artificial intelligence (AI) solutions for breast cancer screening. The company focuses on improving the efficiency, safety, quality, and precision of breast health services. Densitas® offers products that equip mammography facilities with tools to enhance mammography quality, optimize operational efficiency, reduce clinical care team burnout, standardize breast density assessments, and simplify compliance with regulations like MQSA EQUIP.
Key Figures
- Founder & CEO: Mo Abdolell
- Employees: 30
- Estimated Annual Revenue: $3.5M
- Funding Raised: $363K over two rounds
- Recent Funding Round: Seed funding of $360K on June 12, 2019
Mission and Values
Densitas’ mission is to empower breast cancer screening providers to enhance outcomes via evidence-based AI solutions. The company's core values include:
- Customer-Centricity: Prioritizing the customer in all decisions.
- Innovation: Leveraging clinical experience and scientific rigor to drive innovation.
- Collaboration: Fostering a collaborative and respectful work environment.
- Duty of Candor: Valuing honesty, integrity, and accountability.
- Impact: Creating scalable and sustainable breast health solutions for population health management.
Product and Service Offerings
Densitas provides an array of AI-powered solutions designed to impact various aspects of breast cancer screening:
- Mammography Quality: Enhancing image quality and operational efficiencies.
- Analytics: Advanced breast density and risk reporting tailored for improving decision-making processes.
- Breast Density Solution: Standardizing assessments and informing technologist training protocols for improved accuracy.
- intelliMammo® and intelliMaven™: AI platforms for integrating digital workflows and quality standards, aimed at significantly reducing burnout among clinical care teams.
Advisory Board
- Dr. Georgia Spear: Chief of the Department of Breast Imaging at NorthShore University HealthSystem, advocate for personalized breast cancer screening.
- Dr. Eliot Siegel: Expert in imaging informatics, Vice-Chair at the University of Maryland School of Medicine, and Chief of Radiology at VA Maryland Healthcare System.
- Dr. Nisha Sharma: Director of the Breast Screening program at Leeds Teaching Hospital NHS Trust, UK.
- Dr. Judy Caines: Former Medical Director of the Nova Scotia Breast Screening Program, advocate for multidisciplinary approaches in breast disease diagnosis.
Partnerships and Recent Developments
Densitas has announced strategic partnerships to expand their market reach and capabilities, including collaborations with organizations like Intelerad Medical Systems. Recently, the company launched intelliMaven™, a next-gen AI solution aimed at elevating mammography quality standards.
Online Presence and Contact
- Website: [Densitas](https://densitashealth.com/)
- LinkedIn: [Densitas Inc. LinkedIn](https://ca.linkedin.com/company/densitas-inc-)
Competitors
Qure.ai
Qure.ai is a prominent player in the AI healthcare sector, focusing on automating the interpretation of radiology exams such as X-rays, CT scans, and ultrasounds.
Key Highlights:
- Founded: 2016
- Core Technology: Deep learning for automated radiology exam interpretation.
- Key Products: qXR, qER, qCT-Lung designed to facilitate faster diagnosis and treatment.
- Funding: Raised significant Series A and other rounds from prominent investors.
- Global Reach: Features WHO endorsements and FDA clearances for specific products.
Perspectum
Perspectum delivers advanced digital imaging technologies, primarily focusing on liver disease, diabetes, and cancer diagnostics.
Key Highlights:
- Key Products: A range of digital technologies that extract biomarkers from imaging to provide a comprehensive diagnosis.
- Innovations: Leading advancements in precision medicine, especially notable for heart health assessments in long COVID patients.
- Major Collaborations: Strategic partnerships to further clinical trials and research.
Subtle Medical
Subtle Medical focuses on deep learning solutions to enhance medical imaging efficiency and safety.
Key Highlights:
- Founders: Formed by Greg Zaharchuk, MD, Ph.D., and Enhao Gong, Ph.D.
- Key Technologies: Products like SubtlePET™ and SubtleMR™ enhance image quality and workflow efficiency.
- Funding: Over $45 million raised.
- Global Impact: Deployed on hundreds of scanners worldwide, emphasizing fast and reliable diagnoses.
VUNO
VUNO is a Korean-based AI company specializing in AI solutions for various medical fields.
Key Highlights:
- Core Solutions: Range of AI-based diagnostic tools like VUNO Med®-BoneAge™ and VUNO Med®-DeepBrain® focusing on bone age assessment and brain disease quantification respectively.
- Global Influence: Recognized for significant contributions to the AI healthcare space, including solutions for chest X-ray screening and cardiac arrest risk detection.
Arterys
Arterys utilizes cloud-based AI technology to improve medical imaging analytics.
Key Highlights:
- Recent Acquisition: Acquired by Tempus Labs, elevating its capacity to integrate with comprehensive patient data systems.
- Technology: Provides advanced software for accurate and consistent image quantification, enhancing clinical decision-making.
Competitive Analysis
Densitas Inc. stands strong amidst a competitive landscape with significant advancements in AI-driven mammography solutions. Key differentiators include:
- Exclusive Focus: A concentrated focus on breast cancer screening provides specialized expertise.
- AI Integration: Leveraging AI to enhance mammography, making screening more effective and efficient.
- Strategic Partnerships: Continued expansion through partnerships solidifies their market position.
Despite strong competition from innovators like Qure.ai and Perspectum in broader medical imaging and diagnostics, Densitas Inc.’s specialized niche in breast cancer screening keeps it at the forefront of mammography solutions, promising continued growth and innovation.
